Iodine status among pregnant women after mandatory salt iodisation

I. Anaforoğlu1*, E. Algün1, Ö. İnceçayır1, M. Topbaş2 and M. F. Erdoğan3
1Department of Endocrinology and Metabolism, Trabzon Kanuni Education and Research Hospital, 61290 Trabzon, Turkey
2Department of Public Health, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey
3Department of Endocrinology and Metabolism, Faculty of Medicine, Ankara University, 06100 Ankara, Turkey

(Submitted 21 April 2015 – Final revision received 8 October 2015 – Accepted 19 October 2015 – First published online 24 November 2015)

Abstract
I is essential for thyroid hormone synthesis and neurological development. Various changes occur in thyroid hormone metabolism during pregnancy and I requirements increase significantly. The purpose of this study was to investigate I status among pregnant women in Trabzon, formerly a severely I-deficient area but shown to have become I sufficient following mandatory iodisation of table salt based on monitoring studies among school-age children (SAC) in the area. A total of 864 healthy pregnant women with a median age of 28 (25th–75th percentile 17–47) years participated in the study. None of them were using I-containing supplement. All of them were screened for use of iodised salt, obstetric history, thyroid function tests and urinary I concentrations (UIC), and thyroid ultrasonography was performed. Median UIC was 102 (25th–75th percentile = 62–143) µg/l. Median UIC of the patients according to trimesters were 122 µg/l at the 1st, 97 µg/l at the 2nd and 87 µg/l at the 3rd trimester. UIC in the 1st trimester was higher compared with the 2nd and 3rd trimesters (P < 0.017). Nodules were present in 17.7 % of women (n 153). The rate of iodised salt usage among pregnant women was 90-7 %. Our study demonstrates that, although the I status among SAC has been rectified, I deficiency (ID) is still prevalent among pregnant women. Current knowledge is in favour of I supplementation in this group. Until the effects of maternal I supplementation in mild ID have been clarified by large-scale prospective controlled trials, pregnant women living in borderline deficient and I-sufficient areas, such as Trabzon city, should receive 100–200 µg/d of I-containing supplements in addition to iodised salt.

Key words: Thyroid: Pregnancy: Iodine: Iodine deficiency: Iodine supplementation

I deficiency (ID) is recognised as a public health problem across the world. Severe ID throughout pregnancy increases the risk of mental retardation, may harm brain development and intelligence development. ID may also lead to goitre formation during pregnancy.1,2

I requirements increase during pregnancy and breast-feeding. The fetus is highly dependent on maternal thyroxine sources for its neurodevelopment until its own thyroid gland begins to function. After formation of the fetal thyroid gland, fetal thyroid hormone production increases, contributing to increased maternal I requirements. As the maternal glomerular filtration rate increases from the beginning of early pregnancy, iodide filtration increases, resulting in a reduced circulating pool of plasma I. Thyroid hormone demand thus increases from the early weeks of gestation, and this necessitates an adequate I supply.1–3

The WHO recommends a daily I intake of 150 µg/d for non-pregnant women and 250 µg/d for pregnant and lactating women.4 Low median maternal I concentration (UIC) values have been reported in the last few years in pregnant American women.5 The American Thyroid Association, the Endocrine Society and the Neurobehavioral Teratology Society have recommended that women planning a pregnancy or who are pregnant or lactating should receive 150 µg/d I-containing supplements.6–8. However, data from the National Health and Nutrition Examination Survey (2001–2006) showed that only a small percentage (20 %) of pregnant American women routinely took an I-containing supplement.9 Routine I supplementation is also recommended in Europe, but this is not systematically applied in many European countries.10

Goitre prevalence below 5 % in a population indicates that salt iodisation in that region is sufficient.4 Goitre regression usually lags behind urinary I increment for about 1 or more years; the measurement of UIC is recommended in order to demonstrate the success of such programmes.4 Although many urine samples (twelve samples or more) are required for individual measurements, studies have reported that one sample is sufficient for population surveys. In all, 500 spot urine samples are reported to be adequate to describe a population's median I excretion with approximately 5 % precision.11 This is clarified in a subsequent study by the same group. They state that the median I concentration of spot urinary samples

Abbreviations: ID, iodine deficiency; SAC, school-age children; TSH, thyroid-stimulating hormone; UIC, urinary iodine concentrations.

* Corresponding author: I. Anaforoğlu, fax +90 462 230 2307, email ianaforoglu@hotmail.com
obtained from at least 500 subjects is a reliable measure of the I intake of the population\(^{(12)}\).

Erdogan et al.\(^{(13)}\) identified ID in various regions of Turkey by conducting surveys among school-age children (SAC) between 1997 and 1999. Monitoring studies performed after the mandatory iodisation of table salt in 2007 showed that ID had been eradicated in most regions of the country\(^{(14)}\). Trabzon was defined as an I-sufficient area in 2007 with a median UIC of 145 \(\mu\)g/l among SAC\(^{(15)}\).

The number of studies regarding I status in pregnant women is limited. Studies carried out in Turkey to date have been mainly local with small samples. The purposes of this study were to investigate I status in pregnant women in Trabzon, a severely I-deficient area in 1997, which is now reported to be I sufficient, according to SAC 1 surveys conducted in 2007, following mandatory iodisation of table salt in 1999, and to propose relevant I supplementation for pregnant women who are prone to ID\(^{(13,14)}\).

**Methods**

The present study was carried out in Trabzon province, which has a pregnant women population of approximately 4500/year, between September 2011 and September 2012. The sample size was calculated using the formula:

\[
n = \frac{DEFF \times N \times (1-p)}{(d^2/Z^2) - a/2 \times (N-1) + p \times (1-p)),
\]

where the number calculated was 843, the number planned was 1000 and the number included was 864 (DEFF = design effect = 1; \(p = 0.50\); \(d = 0.05\); \(z = 1.96\); \(N = 4500\); \(a = 0.05\); power = 99 %)\(^{(16)}\). Lists of pregnant women registered with family health physicians were obtained, and 1000 women were selected by systematic sampling. Their names were given to family health physicians and these women were then invited to participate in the study. Registered pregnant women were referred by family health physicians. Family health clinics were visited in cases where pregnant women were unable to attend our clinic. Mean age of the pregnant women was 28 (25th–75th percentile 17–47) years; 29.5 % were in the 1st trimester, 35.5 % were in the 2nd and 35 % were in the 3rd trimester (n = 255, 307 and 302, respectively). Women in weeks 1–13 of gestation represented the 1st trimester, women in weeks 14–27 the 2nd trimester and women in weeks 27–40 represented the 3rd trimester. None of the pregnant women were using I-containing supplements. Fasting blood and urine samples were collected, and levels of thyroid-stimulating hormone (TSH), free triiodothyronine (T3), free thyroxine (T4), anti-thyroglobulin (anti-Tg) and anti-thyroid peroxidase (anti-TPO) were determined from the serum. Immunochemiluminescent assays performed on an automated analyzer (Advia Centaur XP; Siemens\(^{(17)}\)) were used to measure levels of TSH, free T3, free T4, anti-Tg and anti-TPO. Thyroid ultrasonography (TUSG) was performed on 820 women. Ultrasonography (USG) was performed using a Hitachi 12 MHz USG device (Hitachi) on the 247 pregnant women who attended the hospital and using a portable Chison 7.5 MHz USG device (Chison) for the 573 women examined at family health clinics, by the same observers on all occasions (I. A., O. I.). The inter-observer variability among the two sonographers was assessed in twenty patients and it was <15 %. Urine samples collected at family health clinics were transferred to the hospital daily. Samples collected at family health clinics and at the hospital were all stored in de-iodised tubes at −40°C. A single spot urine sample was collected in the morning (between 09:00 and 12:00 hours) from each participant. UIC was measured using the spectrophotometric method described by Sandell & Kolthoff\(^{(18)}\). The I laboratory is a part of the Ensuring the Quality of Iodine Procedures (EQUIP) programme conducted by the Center for Disease Control (CDC), USA, since 2009. The I laboratory is externally controlled by the 2013–2014 EQUIP programme, three times per year, and our average success as decided by the CDC is 75–80 %/year. A standard questionnaire was administered by either a training nurse or the relevant physician (I. A.). Demographic data, monthly income, iodised salt usage (i.e., consumption without cooking) and storage conditions (protecting the salt against humidity or light) were recorded. Pregnant women with a known history of any thyroid disease (nodular goitre, thyroiditis, hypothyroidism, hyperthyroidism, history of any thyroid operation or use of any medication for any thyroid disease) were excluded.

Statistical Package for the Social Sciences (SPSS) software (SPSS version 16.0; SPSS Inc.) was used for the statistical analyses. Standard descriptive analysis was used. Data normality was assessed using the Kolmogorov–Smirnov test and ANOVA (Bonferroni test as post hoc) for normally distributed data and the Mann–Whitney U test and the Kruskal–Wallis test (Mann–Whitney U test with Bonferroni correction as post hoc) for non-normally distributed data. Results are shown as arithmetic means and standard deviations for normally distributed data and medians and 25th–75th percentile for non-normally distributed data. \(P < 0.05\) was considered to be significant.

All women invited to take part were provided with written information about the study, and written consent was obtained from all the participants. The study was approved by the local ethics committee of Trabzon Karunii Education and Research Hospital (Approval No. 27.12.2010-8/2010).

**Results**

The median UIC was 102 (25th–75th percentile = 62–143) \(\mu\)g/l. Table 1 summarises the results of UIC in pregnant women including distribution of UIC by trimesters. UIC was >150 \(\mu\)g/l in only 191/864 (22.1 %) women and <150 \(\mu\)g/l in 673/864 (77.9 %) women. UIC in the 1st trimester was higher compared with the 2nd and 3rd trimesters. The median UIC was 122 \(\mu\)g/l at the 1st, 97 \(\mu\)g/l at the 2nd and 87 \(\mu\)g/l at the 3rd trimester (\(P < 0.017\) (Table 1). Thyroid function tests in terms of trimester are given in Table 2. Mean TSH values (reference range: 0.35–5.5 \(\mu\)IU/ml\(^{(18)}\)) were 1.7 (SD 2.9), 1.7 (SD 1.2) and 2.1 (SD 3.1) \(\mu\)IU/ml, respectively, in the 1st, 2nd and 3rd trimesters (\(P < 0.001\); for all trimesters). Free T4 and T3 values decreased significantly during pregnancy (\(P < 0.001\); for all trimesters).

The mean thyroid volume was 12.9 (SD 7.5) ml. Of the study population, 14.8 % (n = 121) had thyroid volumes exceeding 18 ml. There was no correlation between thyroid volume and trimester.
Iodine status among pregnant woman

Median UIC of SAC in that community must be >1st trimester (n 255) 122 77 150 >2nd trimester (n 307) 97 57 140 T <3rd trimester (n 302) 87 54 134 200 µg/l indicates severe ID (4). However, pregnant women, median UIC >150 µg/l is insufficient, and it should be between 150 and 249 µg/l for this population (4).

I status of SAC in Trabzon was reported to be severely deficient (median UIC of 14 µg/l) in a national survey conducted between 1997 and 1999 (13). Following the mandatory iodisation of table salt with 25–40 mg/kg KIO₃ or 50–70 mg/kg KI, monitoring studies in 2002 and 2007 determined median UIC of 113 and 145 µg/l, respectively, among SAC in Trabzon, showing that the province was insufficient (14,15).

These nationwide monitoring studies of SAC by Erdoğan et al. (13,14,19) showed a significant correction of ID, especially in urban areas. However, previous studies among the pregnant population were limited and involved small sample sizes (20–26). These small-sized studies among pregnant women from different regions of Turkey reported median UIC between 77-4 and 149-7 µg/l and that 49-6–100 % of pregnant women were at risk of ID (20–26). Although the median UIC of SAC from most of these areas was sufficient or mildly deficient, ID was still a common problem among pregnant women (20–26).

Current data from the Trabzon provincial centre, formerly endemic but currently an I-sufficient region in the light of SAC surveys, show that the population median UIC is below the WHO threshold of adequacy in all three trimesters of pregnancy. The use of iodised salt in the region among the pregnant population needs additional I support from the 1st trimester onwards. Large-scale monitoring studies recently conducted...
among pregnant women from the cities of Ankara and Istanbul also support our results (A Aktaş, Ü Aydın, Bİ Aydoğan, K Erkenekli, G Koç, Z Berberoğlu, Y Aral, MF Erdoğan, unpublished results, and E Oral, AS Açıklar, B Aydoğan, Bİ Aydoğan, Hİ Acıkoğlu, GA Ilhan, B Dane, A Özel, H Erenel, B Tandoğan, E Çakar, H İşi, B Kayan, H Aslan, A Ekiz, S Sancak, A Çelik, T Yoldemir, Ö Uzun, MF Erdoğan, unpublished results). The results of the 1st study performed among 312 pregnant women showed that 76, 82 and 91 % of women from the city of Istanbul is described as I-sufficient(14), one multicentre study involving 3543 pregnant women from nine different gynaecology and obstetrics clinics from the city of Istanbul, conducted in 2013, showed that 90-7 % of pregnant women were I deficient during the 1st, 2nd and 3rd trimesters of pregnancy, respectively (A Aktaş, Ü Aydın & Bİ Aydoğan, unpublished results).

Similarly, although Istanbul is described as an I-sufficient city(14), one multicentre study involving 3543 pregnant women from nine different gynaecology and obstetrics clinics from the city of Istanbul, conducted in 2013, showed that 90-7 % of pregnant women were I deficient during pregnancy (E Oral, AS Açıklar & B Dane, unpublished results). UIC measured from single samples from pregnant women was not associated with history of stillbirth, congenital anomalies or spontaneous abortus, in agreement with our study results (E Oral, AS Açıklar & B Dane, unpublished results).

The consequences of severe ID during pregnancy and lactation are well known, whereas studies concerning the effects of mild-to-moderate ID are inconsistent(27). A recent observational study of 1040 mothers and their children showed that even mild ID in utero is linked to lower intelligence quotient and suboptimal reading ability in 8-year-old children(28). Children’s scores worsened when the deficient group (UIC < 150 µg/l) was subdivided into groups with UIC between 50 and 150 µg/l and those with UIC < 50 µg/l(29). Similarly, a study from Tasmania showed that children whose mothers had UIC < 150 µg/l during pregnancy scored 10 % lower in spelling, 7-6 % in grammar and 5-7 % in English literacy performance compared with children whose mothers had UIC > 150 µg/l(29). Another study from the Netherlands showed that low maternal UIC during pregnancy is associated with impaired executive functioning in children(30).

Among intervention studies examining the impact of maternal I supplementation on the neurodevelopment of children, Velasco et al.(31) observed that children of I-supplemented mothers exhibited better behavioural and psychomotor performance than those of untreated mothers. In a study of development quotient from Spain, delayed neurobehavioural performance was reported to be higher in children whose mothers did not receive supplementation from early pregnancy(32).

Murcia et al.(33) reported lower psychomotor development indices among infants whose mothers received >150 µg/d of I supplementation than those of mothers receiving <100 µg/d. In contrast, Santiago et al.(34) determined no difference in terms of mental development or psychomotor scales, between mothers using iodised salt or I supplementation. A recently published study from the Netherlands also detected no association between maternal low UIC and children’s cognition. In that study, the authors stated that the research was not powerful enough to detect a significant association because the number of women with ID was very low(35). Finally, a large meta-analysis investigating the effects of maternal I supplementation concluded that large-scale controlled, prospective trials are needed to clarify the situation(36).

We found no difference when our results were stratified by the use of iodised salt, awareness of the importance of I in pregnancy, education level or monthly income. This may be due to the use of spot and single urine examples, as this was a population survey study. More samples per participant (e.g. ten to twelve independent urine samples per participant) could yield I status at the individual level. More participants, with only
Iodine status among pregnant woman

single spot urine per participant, may not appreciably add to the
interpretation of population median values as conducted in
the present study and would not increase the interpretive value for
individuals. As described in two different reviews, analyses of as
few as two independent urine samples per participant, followed
by appropriate statistical modelling to remove within-individual
variation, could yield fully interpretable population distributions
of habitual UIC, which could be effectively used to evaluate
proportion of the study below a threshold\(^{37,38}\).

ID levels as well as TSH levels increased by trimester in our
study. Median UIC were lower in the 2nd and 3rd trimesters.
Free T3 and free T4 levels in the serum decreased parallel to the
increase in TSH and decrease in median UIC. These findings
may partly be explained by physiological changes in thyroid
hormone metabolism in pregnancy (i.e. dilution or an increasing
glomerular filtration rate and increasing I demand), as well as
the worsening of I status during the trimesters\(^{1-4}\).

In terms of thyroid nodularity (the prevalence of nodule in the
general population), the 35-2\% prevalence rate reported by a
prevalence study performed in our region by Koçak et al\(^{39}\) was
considerably higher than that in our population. However,
the prevalence of nodules in the young population (20-29 years) in
that study was 12.5\%, rising to 38.4\% in individuals aged over
70 years\(^{39}\). Similarly, overall goitre prevalence was higher than
that in our population (14.8 v. 28.4\%), and there was a significant
increase in volume with advancing age. In this formerly I-deficient
area, prevalence of goitre was 12.5\% in the 20-29 years age
group and 38.4\% in the over 70 years age group\(^{39}\).

Iodised salt stored in open containers may lose 50–100\% of its
I content due to humidity and other factors when KI is used for
iodisation\(^{40}\). Similarly, Wang et al\(^{41}\) reported that iodised salt
loses 2-63\% of its I content when salt is added before or early
during cooking. In all, 25\% of the women in our study stored
iodised salt appropriately, and 65\% added iodised salt properly
after cooking. Fortunately KIO\(_3\) which is much more stable than
KI, has been used for salt iodisation in Turkey since 2010\(^{42}\).

In conclusion, despite the global I supplementation
programme, which has improved I status worldwide, ID is still a
serious health problem, especially among pregnant women.
Current knowledge is in favour of I supplementation in this risk
group. Until the effects of maternal I supplementation, in mild
ID, are clarified by large-scale prospective controlled trials,
pregnant women living in borderline deficient and I-sufficient
areas, such as Trabzon city, should receive 100–200\(\mu\)g/d
I-containing supplements in addition to iodised salt, depending
on the severity of deficiency among SAC.

Acknowledgements

The authors thank the family physicians for providing lists of
registered pregnant women and inviting them to participate in
the study. The authors also thank the nurse Ebru Güneykaya
and the secretaries Hatice Koçak and Seygi Özer for their
secretarial assistance.

This research received no specific grant from any funding
agency, commercial or not-for-profit sectors.

The authors’ contributions are as follows: I. A., E. A. and
M. F. E. designed the study; I. A. and O. I. collected data;
I. A. drafted the paper; I. A. and M. F. E. wrote the manuscript;
and I. A., M. F. E. and M. T. were responsible for data analyses
and data interpretation. M. F. E. critically read and revised the
paper. All the authors read and approved the final version of
the manuscript.

The authors declare that there are no conflicts of interest.

References

97, 137–148.

2. Burrow GN, Fisher DA & Larsen PR (1994) Maternal and

3. Leung AM, Pearce EN & Braverman LE (2011) Iodine nutrition
in pregnancy and lactation. Endocrinol Metab Clin North Am
40, 765–777.

4. World Health Organization, United Nations International
Children’s Emergency Fund & ICCIDD (2007) Assessment of
Iodine Deficiency Disorders and Monitoring Their Elimination

Guidelines of the American Thyroid Association for the diag-
nosis and management of thyroid disease during pregnancy
and postpartum. Thyroid 21, 1081–1125.

in pregnant women in the National Children’s Study and in
U.S. women (15–44 years), National Health and Nutrition

Management of thyroid dysfunction during pregnancy and
postpartum: an Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab 97, 2543–2565.

public affairs committee position paper: iodine deficiency in

9. Gregory CO, Serdula MK & Sullivan KM (2009) Use of sup-
plements with and without iodine in women of childbearing
age in the United States. Thyroid 19, 1019–1020.

of pregnant women in Europe: a review and recommenda-

Reliability of studies of iodine intake and recommendations
for number of samples in groups and individuals. Br J Nutr
99, 813–818.

iodine intake from various urinary iodine measurements in
population studies. Thyroid 19, 1281–1286.

and goiter prevalence in Turkey before mandatory iodina-


decade of iodine prophylaxis is needed to eradicate goiter
among school age children in a moderately iodine-
deficient region. Thyroid 19, 265–268.


sensitivity of seven automated thyroid stimulating hormone


